By Gwendolyn Wu | Published August 31, 2026
In a significant development for the burgeoning field of cell therapy, two pharmaceutical giants—Novartis and Bristol Myers Squibb (BMS)—have hit a major regulatory and clinical roadblock. Both companies announced on Monday that they are pausing pivotal clinical trials for their respective CAR-T (chimeric antigen receptor T-cell) therapies targeting autoimmune diseases. The voluntary holds, triggered by the emergence of concerning inflammatory side effects, cast a long shadow over the industry’s high-stakes ambition to repurpose cancer-fighting technology as a "cure" for chronic immune conditions.
The Main Facts: Safety Signals Halt Progress
The pause centers on two promising therapies: Novartis’s "rap-cel" and Bristol Myers’s "zola-cel" (zolacabtagene autoleucel). Both therapies were designed to leverage the power of the body’s own immune system to eliminate the rogue cells responsible for autoimmune disorders, such as systemic lupus erythematosus (SLE), myasthenia gravis, and multiple sclerosis.
Novartis’s decision follows the observation of three cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS)—a rare, aggressive, and potentially life-threatening hyper-inflammatory reaction—within its rap-cel program. Consequently, the company suspended trials across a wide range of indications on August 24.
Simultaneously, Bristol Myers Squibb has voluntarily paused enrollment for its zola-cel trials. While the company described the move as a precautionary measure, the suspension stems from the detection of "transient and reversible inflammatory events" identified during routine safety surveillance. These developments represent a stark reminder that while CAR-T therapies have revolutionized oncology, their application in non-malignant conditions carries a different, and perhaps more nuanced, safety profile.
A Chronology of the Safety Concerns
The optimism surrounding the "immune reset" approach has been building for years, fueled by early academic successes that suggested CAR-T could drive recalcitrant autoimmune diseases into long-term remission. However, the recent events highlight the volatility of these clinical programs:
- February 2026: Initial safety data regarding zola-cel was published, documenting a singular case of IEC-HS during an early-stage Phase 1 study. At the time, the incident was categorized as consistent with the known, albeit manageable, risks of CAR-T therapies.
- August 24, 2026: Novartis formally initiated clinical holds on its rap-cel trials, encompassing studies in lupus, myasthenia gravis, and multiple sclerosis, following the identification of the three aforementioned IEC-HS cases.
- August 31, 2026: Both Novartis and Bristol Myers Squibb publicly acknowledged the pauses, citing the need for a comprehensive data review to ensure patient safety before proceeding with further enrollment.
Supporting Data and Technical Nuance
Central to this disruption is the evolution of the manufacturing processes behind these therapies. Both rap-cel and zola-cel utilize next-generation technology designed to shorten production times compared to the first wave of oncology CAR-T products.
Analysts, including William Blair’s Sami Corwin, have suggested that these expedited manufacturing platforms—while commercially attractive—might be contributing to the adverse events. "This technology could be driving increased cell expansion," Corwin noted in a recent client briefing, "and the reported toxicities may be an indirect consequence of the heightened potency or kinetics of these cells once infused."
The toxicity profiles, specifically IEC-HS, are complex. In oncology, clinicians are accustomed to managing cytokine release syndrome (CRS) and neurotoxicity. However, applying these treatments to patients with autoimmune conditions—who are often physically fragile and suffering from long-term inflammation—requires a recalibration of the risk-benefit analysis. The fact that Bristol Myers continues to see "transient and reversible" events suggests that while these therapies are highly active, the threshold for systemic inflammation in these patients may be significantly lower than in oncology patients.
Official Responses: Navigating Regulatory Scrutiny
Both companies are currently engaged in intense dialogue with global regulatory bodies to determine the next steps.
"The temporary halt will allow for a more comprehensive review of the evolving clinical and safety data across the program," a Novartis spokesperson stated in an email to BioPharma Dive. The company underscored that while the autoimmune studies are paused, its ongoing oncology trials for rap-cel remain unaffected, suggesting the issue may be specific to the underlying biology of the autoimmune patient population.
Bristol Myers Squibb adopted a similarly measured tone. Despite the pause, the company remains firm in its commitment to the zola-cel platform. "We continue to have confidence in zola-cel, which has demonstrated transformational, treatment-free responses in SLE and other autoimmune diseases," a company representative noted. The company maintains that the therapy’s safety profile remains within the expected boundaries of the CAR-T class and is working to resume testing as soon as safely possible.
Broader Implications for the Cell Therapy Market
The implications of these pauses extend far beyond Novartis and BMS. The "immune reset" sector is currently one of the hottest areas in biotechnology, with several other players vying for market dominance.
The Competitive Landscape
- Cabaletta Bio: Currently operating multiple clinical trials, including a pivotal study in myositis, the company is watching the Novartis/BMS situation closely.
- Kyverna Therapeutics: A significant player in this space, Kyverna is moving toward a potential approval application for stiff person syndrome and is actively enrolling patients in a pivotal myasthenia gravis study.
The Path Forward: Market Adoption and Confidence
The "wait and see" approach now being adopted by regulators and sponsors could delay the arrival of these life-changing therapies by months, or in some cases, years. If the toxicities are linked to the manufacturing speed or the specific receptor design, companies may be forced to refine their protocols, which could lead to significant cost increases or diminished efficacy.
"This will clearly need to be monitored to determine how it could impact the total market adoption of these products in the future," says Corwin. Investors are particularly sensitive to these signals; a "pause" is often a precursor to a "pivot," and any long-term safety concerns could lead to restricted labeling or the need for more rigorous patient selection criteria—factors that would directly impact the total addressable market for these multi-billion-dollar potential therapies.
Conclusion: The Price of Innovation
The recent setbacks for Novartis and Bristol Myers Squibb are not necessarily the end of the line for autoimmune CAR-T therapy, but they are a definitive "speed bump" in a high-speed race. The scientific community remains largely convinced that the ability to "reboot" an immune system—essentially wiping the slate clean of disease-causing B-cells—is a landmark therapeutic goal.
However, as the field matures, the transition from oncology to immunology is proving to be more complex than expected. The biological reality of treating systemic inflammatory diseases with potent, engineered cells requires a level of precision that is still being refined. For now, the industry must balance the urgent demand for better treatments with the uncompromising necessity of patient safety. As these companies dive deeper into their data, the rest of the biotech world will be watching, waiting to see if these toxicities are an inherent limitation of the therapy or merely a hurdle that can be cleared with better dosing, timing, and patient monitoring.
The promise of a "treatment-free" life for patients with severe autoimmune disease remains the ultimate prize, but as of this week, that prize feels slightly more distant, underscored by the sobering reality of clinical development.
